Prediction Models for Celiac Disease Development in Children From High-Risk Families: Data From the PreventCD Cohort.


Journal

Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630

Informations de publication

Date de publication:
08 2022
Historique:
received: 29 08 2021
revised: 31 03 2022
accepted: 15 04 2022
pubmed: 30 4 2022
medline: 27 7 2022
entrez: 29 4 2022
Statut: ppublish

Résumé

Screening for celiac disease (CD) is recommended in children with affected first-degree relatives (FDR). However, the frequency of screening and at what age remain unknown. The aims of this study were to detect variables influencing the risk of CD development and develop and validate clinical prediction models to provide individualized screening advice. We analyzed prospective data from the 10 years of follow-up of the PreventCD-birth cohort involving 944 genetically predisposed children with CD-FDR. Variables significantly influencing the CD risk were combined to determine a risk score. Landmark analyses were performed at different ages. Prediction models were created using multivariable Cox proportional hazards regression analyses, backward elimination, and Harrell's c-index for discrimination. Validation was done using data from the independent NeoCel cohort. In March 2019, the median follow-up was 8.3 years (22 days-12.0 years); 135/944 children developed CD (mean age, 4.3 years [range, 1.1-11.4]). CD developed significantly more often in girls (P = .005) and in Human Leukocyte Antigen (HLA)-DQ2 homozygous individuals (8-year cumulative incidence rate of 35.4% vs maximum of the other HLA-risk groups 18.2% [P < .001]). The effect of homozygosity DR3-DQ2/DR7-DQ2 on CD development was only present in girls (interaction P = .04). The prediction models showed good fit in the validation cohort (Cox regression 0.81 [0.54]). To calculate a personalized risk of CD development and provide screening advice, we designed the Prediction application https://hputter.shinyapps.io/preventcd/. Children with CD-FDR develop CD early in life, and their risk depends on gender, age and HLA-DQ, which are all factors that are important for sound screening advice. These children should be screened early in life, including HLA-DQ2/8-typing, and if genetically predisposed to CD, they should get further personalized screening advice using our Prediction application. ISRCTN74582487 (https://www.isrctn.com/search?q=ISRCTN74582487).

Sections du résumé

BACKGROUND & AIMS
Screening for celiac disease (CD) is recommended in children with affected first-degree relatives (FDR). However, the frequency of screening and at what age remain unknown. The aims of this study were to detect variables influencing the risk of CD development and develop and validate clinical prediction models to provide individualized screening advice.
METHODS
We analyzed prospective data from the 10 years of follow-up of the PreventCD-birth cohort involving 944 genetically predisposed children with CD-FDR. Variables significantly influencing the CD risk were combined to determine a risk score. Landmark analyses were performed at different ages. Prediction models were created using multivariable Cox proportional hazards regression analyses, backward elimination, and Harrell's c-index for discrimination. Validation was done using data from the independent NeoCel cohort.
RESULTS
In March 2019, the median follow-up was 8.3 years (22 days-12.0 years); 135/944 children developed CD (mean age, 4.3 years [range, 1.1-11.4]). CD developed significantly more often in girls (P = .005) and in Human Leukocyte Antigen (HLA)-DQ2 homozygous individuals (8-year cumulative incidence rate of 35.4% vs maximum of the other HLA-risk groups 18.2% [P < .001]). The effect of homozygosity DR3-DQ2/DR7-DQ2 on CD development was only present in girls (interaction P = .04). The prediction models showed good fit in the validation cohort (Cox regression 0.81 [0.54]). To calculate a personalized risk of CD development and provide screening advice, we designed the Prediction application https://hputter.shinyapps.io/preventcd/.
CONCLUSION
Children with CD-FDR develop CD early in life, and their risk depends on gender, age and HLA-DQ, which are all factors that are important for sound screening advice. These children should be screened early in life, including HLA-DQ2/8-typing, and if genetically predisposed to CD, they should get further personalized screening advice using our Prediction application.
TRIAL REGISTRATION NUMBER
ISRCTN74582487 (https://www.isrctn.com/search?q=ISRCTN74582487).

Identifiants

pubmed: 35487291
pii: S0016-5085(22)00442-5
doi: 10.1053/j.gastro.2022.04.030
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

426-436

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Caroline R Meijer (CR)

Department of Pediatrics, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: c.r.meijer-boekel@lumc.nl.

Renata Auricchio (R)

Translational Medical Sciences and European Laboratory for the Investigation of Food-Induced Disease, University of Naples Federico II, Naples, Italy.

Hein Putter (H)

Department of Medical Statistics, Leiden University Medical Center, Leiden, the Netherlands.

Gemma Castillejo (G)

Pediatric Gastroenterology Unit, Hospital Universitario Sant Joan de Reus, Reus, Spain.

Paula Crespo (P)

ADViSE, Department of Health Sciences, European University Miguel de Cervantes, Hospital Recoletas Campo Grande, Valladolid, Spain.

Judit Gyimesi (J)

Coeliac Disease Centre, Heim Pál National Paediatric Institute, Budapest, Hungary.

Corina Hartman (C)

Institute for Gastroenterology, Nutrition and Liver Disease, Schneider Children's Medical Center, Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel.

Sanja Kolacek (S)

Referral Center Pediatric Gastroenterology and Nutrition, Zagreb University, Medical School, Zagreb, Croatia.

Sibylle Koletzko (S)

Dr. von Hauner Children's Hospital, Department of Pediatrics, University Hospital, LMU Munich, Munich, Germany; Department of Pediatrics, Gastroenterology and Nutrition, School of Medicine Collegium Medicum University of Warmia and Mazury, Olsztyn, Poland.

Ilma Korponay-Szabo (I)

Coeliac Disease Centre, Heim Pál National Paediatric Institute, Budapest, Hungary.

Eva Martinez Ojinaga (EM)

Pediatric Gastroenterology and Nutrition, La Paz University Hospital, Madrid, Spain.

Isabel Polanco (I)

Pediatric Gastroenterology and Nutrition, La Paz University Hospital, Madrid, Spain.

Carmen Ribes-Koninckx (C)

Pediatric Gastroenterology Unit, La Fe Hospital, Valencia, Spain.

Raanan Shamir (R)

Institute for Gastroenterology, Nutrition and Liver Disease, Schneider Children's Medical Center, Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel.

Hania Szajewska (H)

Pediatrics, Warsaw, Medical University of Warsaw, Warsaw, Poland.

Riccardo Troncone (R)

Translational Medical Sciences and European Laboratory for the Investigation of Food-Induced Disease, University of Naples Federico II, Naples, Italy.

Vincenzo Villanacci (V)

Institute of Pathology, ASST-Spedali Civili Brescia, Brescia, Italy.

Katharina Werkstetter (K)

Dr. von Hauner Children's Hospital, Department of Pediatrics, University Hospital, LMU Munich, Munich, Germany.

M Luisa Mearin (ML)

Department of Pediatrics, Leiden University Medical Center, Leiden, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH